H.R.7828: PRICED Act

About This Bill

Bill Version

Bill Summary

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period. This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this...

(Source: Library of Congress)

Bill Actions

Date Description
May 18, 2022
Referred to the House Committee on Energy and Commerce.
May 18, 2022

Introduced in the House by Jan Schakowsky (D-Ill.)

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page